Business
Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip
THE WOODLANDS, TX, April 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"THE WOODLANDS, TX, April 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has entered into a service agreement with NoiseFigure Research, Inc. (NFR), a premier application specific integrated circuits (ASICs) service provider. As part of the agreement, Autonomix will work with NFR to assess its ASIC microchip and upgrade the chip to its second-generation in preparation for human clinical testing in the Company’s planned pivotal trial in 2025. Additionally, NFR will evaluate a subsequent version meant to enable commercial production volumes. Lori Bisson, Chief Executive Officer of Autonomix said, “This collaboration with NFR is an important step in the evolution of our technology and simple approach to a procedure for pain management and other indications. The proprietary ASIC is the real intelligence in our technology that enables us to detect neural activity, amplify nerve signals, convert signals to digital form, and geolocate nerves, with approximately 3000 times greater sensitivity than the closest available sensing technology in the market today. We look forward to working closely with the NFR team and leveraging their expertise.” The Company’s catheter-based technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body. The Company is initially developing its technology to address pancreatic cancer-related pain. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects. For more information about the Company’s technology, please visit autonomix.com. About NoiseFigure Research, Inc. NFR is a leader in democratizing...